Thrombolysis based on magnetically-controlled surface-functionalized Fe3O4nanoparticle.
In this study, the control of magnetic fields to manipulate surface-functionalized Fe3O4nanoparticles by urokinase coating is investigated for thrombolysis in a microfluidic channel. The urokinase-coated Fe3O4nanoparticles are characterized using particle size distribution, zeta potential measurement and spectroscopic data. Thrombolytic ratio tests reveal that the efficiency for thrombus cleaning is significantly improved when using magnetically-controlled urokinase-coated Fe3O4nanoparticles than pure urokinase solution. The average increase in the rate of thrombolysis with the use of urokinase-coated Fe3O4nanoparticles is about 50%. In vitro thrombolysis test in a microfluidic channel using the coated nanoparticles shows nearly complete removal of thrombus, a result that can be attributed to the clot busting effect of the urokinase as it inhibits the possible formation of blood bolus during the magnetically-activated microablation process. The experiment further demonstrates that a thrombus mass of 10.32 mg in the microchannel is fully removed in about 180 s.
a College of Mechanical Engineering and Automation , Huaqiao University , Xiamen, Fujian , China.|b Department of Mechanical Engineering , Chung Yuan Christian University , Chung Li , Taiwan.
Ming
M
Chang
b Department of Mechanical Engineering , Chung Yuan Christian University , Chung Li , Taiwan.
Yu-Hao
YH
Lin
c Mapua Institute of Technology , Intramuros, Manila , Philippines.
Jacque Lynn
JL
Gabayno
d The State Key Laboratory of Digital Manufacturing Equipment and Technology , Huazhong University of Science and Technology , Wuhan , China.
Qian
Q
Li
d The State Key Laboratory of Digital Manufacturing Equipment and Technology , Huazhong University of Science and Technology , Wuhan , China.
Xiaojun
X
Liu
D020099:Coated Materials, Biocompatible / Q000737:chemistry; D016503:Drug Delivery Systems; D004800:Enzymes, Immobilized / Q000737:chemistry / Q000494:pharmacology; D052203:Ferrosoferric Oxide / Q000737:chemistry*; D006801:Humans; D044085:Microfluidics; D008962:Models, Theoretical; D053758:Nanoparticles / Q000737:chemistry*; D010316:Particle Size; D015912:Thrombolytic Therapy / Q000379:methods*; D013927:Thrombosis / Q000188:drug therapy*; D014568:Urokinase-Type Plasminogen Activator / Q000737:chemistry / Q000494:pharmacology*
D020099:Coated Materials, Biocompatible; D004800:Enzymes, Immobilized; D014568:Urokinase-Type Plasminogen Activator; D052203:Ferrosoferric Oxide
Fe3O4 nanoparticles; magnetic-control; magnetically-activated microablation; surface-functionalized; thrombolysis; urokinase
Cerebrovasc Dis. 2005;19(4):225-8
15703466
Nature. 2008 Feb 21;451(7181):914-8
18288180
Nanotechnology. 2010 Nov 5;21(44):445601
20935349
PLoS One. 2012;7(10):e40388
23056167
Int J Stroke. 2015 Aug;10(6):956-68
23336348
Exp Ther Med. 2013 Oct;6(4):1015-1021
24137308
Nanoscale. 2015 Mar 7;7(9):3947-53
25652797
Stroke. 1988 Jul;19(7):802-12
3388452